6:30 PM
 | 
Mar 30, 2010
 |  BC Extra  |  Company News

Luveniq receives Priority Review

FDA accepted for filing and granted Priority Review to an NDA from Lux Biosciences Inc. (Jersey City, N.J.) for Luveniq voclosporin to treat non-infectious...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >